Notably, CYP46A1 offers a promising therapeutic avenue for neurological conditions, as evidenced by alterations in 24S-hydroxycholesterol—a marker closely linked to its function—across disorders such as AD, PD, HD, Niemann–Pick disease type C, and spinocerebellar ataxia [44,49,53,56,137,138]. This evidence concerns the gene CYP46A1 and Parkinson disease.